Multiple imputation methodology is reflective of secukinumab efficacy in real clinical practice: Data from the FIXTURE and ERASURE studies in moderate to severe plaque psoriasis

被引：0
|
作者：
Langley, Richard [1 ]
Reich, Kristian [2 ,3 ]
Papavassilis, Charms [4 ]
Fox, Todd [4 ]
Gong, Yankun [5 ]
Guettner, Achim [4 ]
机构：
[1] Dalhousie Univ, Halifax, NS, Canada
[2] Dermatologikum Hamburg, Hamburg, Germany
[3] SCIderm Res Inst, Hamburg, Germany
[4] Novartis Pharma AG, Basel, Switzerland
[5] Beijing Novartis Pharma Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P047
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [31] Efficacy of treatment with secukinumab in difficult-to-treat moderate-severe psoriasis in real clinical practice. A series of 15 cases
    Aceituno Madera, P.
    Moreno Suarez, F.
    Salazar Nievas, M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB55 - AB55
  • [32] Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania
    Bucur, Stefana
    Serban, Elena-Daniela
    Ileanu, Bogdan Vasile
    Costache, Raluca Simona
    Nicolescu, Alin Codrut
    Constantin, Traian
    Costache, Daniel Octavian
    Constantin, Maria -Magdalena
    PSORIASIS-TARGETS AND THERAPY, 2024, 14 : 79 - 86
  • [33] Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience
    Gonulal, Melis
    Altunay, Ilknur Kivanc
    Dogan, Sinan
    Turkmen, Meltem
    Balci, Didem Didar
    Ozturkcan, Serap
    DERMATOLOGIC THERAPY, 2022, 35 (12)
  • [34] Secukinumab in psoriasis: Relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials
    Gottlieb, Alice
    Strober, Bruce
    Lebwohl, Mark
    Kaufmann, Roland
    Pariser, David
    Narbutas, Redzinaldas
    Nyirady, Judit
    Zhao, Yang
    Tran, Mary Helen
    McLeod, Lori
    Odom, Dawn
    Elewski, Boni
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB250 - AB250
  • [35] Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
    Blauvelt, Andrew
    Armstrong, April W.
    Langley, Richard G.
    Gebauer, Kurt
    Thaci, Diamant
    Bagel, Jerry
    Guenther, Lyn C.
    Paul, Carle
    Randazzo, Bruce
    Flavin, Susan
    Hsu, Ming-Chun
    You, Yin
    Reich, Kristian
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2317 - 2324
  • [36] Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with moderate-to-severe plaque psoriasis: Results from the EXCEED study
    Gottlieb, Alice B.
    Merola, Joseph F.
    Reich, Kristian
    Behrens, Frank
    Nash, Peter
    Bao, Weibin
    Pellet, Pascale
    Pricop, Luminita
    McInnes, Iain B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB92 - AB92
  • [37] In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis
    Galluzzo, Marco
    D'Adamio, Simone
    Silvaggio, Dionisio
    Lombardo, Paolo
    Bianchi, Luca
    Talamonti, Marina
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (02) : 173 - 182
  • [38] Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis
    Papadavid, E.
    Rompoti, N.
    Theodoropoulos, K.
    Kokkalis, G.
    Rigopoulos, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (07) : 1173 - 1179
  • [39] Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study
    Thaci, D.
    Koerber, A.
    von Kiedrowski, R.
    Bachhuber, T.
    Melzer, N.
    Kasparek, T.
    Duetting, E.
    Kraehn-Senftleben, G.
    Amon, U.
    Augustin, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (02) : 310 - 318
  • [40] Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
    David Pariser
    Ellen Frankel
    Joel Schlessinger
    Yves Poulin
    Ronald Vender
    Richard G. Langley
    Xiangyi Meng
    Adriana Guana
    Judit Nyirady
    Dermatology and Therapy, 2018, 8 : 17 - 32
12345